Abcam (ABC) Stock Rating Reaffirmed by Peel Hunt

Peel Hunt reissued their buy rating on shares of Abcam (LON:ABC) in a report released on Tuesday, April 2nd, ThisIsMoney.Co.Uk reports.

Several other analysts also recently weighed in on the stock. Berenberg Bank reissued a buy rating and set a GBX 1,640 ($21.43) target price on shares of Abcam in a research report on Tuesday, January 8th. JPMorgan Chase & Co. restated a neutral rating on shares of Abcam in a research note on Wednesday, January 2nd. Finally, Numis Securities upgraded shares of Abcam to an add rating and set a GBX 1,340 ($17.51) price objective for the company in a research note on Tuesday, January 8th.

ABC traded up GBX 12 ($0.16) on Tuesday, reaching GBX 1,249 ($16.32). 228,943 shares of the company traded hands, compared to its average volume of 497,233. Abcam has a one year low of GBX 1,006 ($13.15) and a one year high of GBX 1,588 ($20.75). The firm has a market capitalization of $2.57 billion and a price-to-earnings ratio of 44.77.

The business also recently declared a dividend, which was paid on Friday, April 12th. Investors of record on Thursday, March 14th were issued a GBX 3.55 ($0.05) dividend. This represents a yield of 0.32%. The ex-dividend date of this dividend was Thursday, March 14th. Abcam’s payout ratio is presently 0.43%.

About Abcam

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Further Reading: What are the risks of holding treasury bonds?

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.